Pfizer and Johnson & Johnson's Brewing Brawl Gets Real
Pfizer (NYSE: PFE) took direct aim at Johnson & Johnson (NYSE: JNJ) last year when it won FDA approval for Inflectra, a biosimilar to Johnson & Johnson's multi-billion dollar per year autoimmune disease drug, Remicade.
Remicade's market size made Inflectra's approval arguably the most significant approval yet for biosimilars, however, Inflectra's sales have been growing more slowly than expected, and based on a suit just filed by Pfizer, it's Johnson & Johnson that's to blame for its sluggish start.
Image source: Getty Images.
Source: Fool.com
Merck & Co. Inc. Stock
€117.44
-0.540%
The stock is an absolute favorite of our community with 27 Buy predictions and no Sell predictions.
As a result the target price of 123 € shows a slightly positive potential of 4.73% compared to the current price of 117.44 € for Merck & Co. Inc..
